Induction of Adipophilin-Specific Cytotoxic T Lymphocytes Using a Novel HLA-A2-Binding Peptide That Mediates Tumor Cell Lysis
暂无分享,去创建一个
H. Rammensee | S. Stevanović | O. Schoor | L. Kanz | P. Brossart | M. Weck | T. Weinschenk | S. Appel | F. Grünebach | Kerstin Schag | S. Schmidt | Martin R. Müller
[1] L. Kanz,et al. Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells. , 2003, Blood.
[2] P. Brossart,et al. Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes , 2003, Gene Therapy.
[3] G. Bartsch,et al. Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Hans-Georg Rammensee,et al. Integrated functional genomics approach for the design of patient-individual antitumor vaccines. , 2002, Cancer research.
[5] D. Jäger,et al. Clinical cancer vaccine trials. , 2002, Current opinion in immunology.
[6] H. Vosper,et al. The Peroxisome Proliferator-activated Receptor δ Promotes Lipid Accumulation in Human Macrophages* , 2001, The Journal of Biological Chemistry.
[7] L. Kanz,et al. Dendritic cells in cancer vaccines. , 2001, Experimental hematology.
[8] D. Brown,et al. Lipid droplets: Proteins floating on a pool of fat , 2001, Current Biology.
[9] G. Schmitz,et al. Adipophilin is a sensitive marker for lipid loading in human blood monocytes. , 2001, Biochimica et biophysica acta.
[10] J. Clements,et al. Novel association of a diverse range of genes with renal cell carcinoma as identified by differential display , 2000, International journal of cancer.
[11] L. Kanz,et al. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.
[12] A. Enk,et al. Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma , 1999, The Journal of experimental medicine.
[13] E. Gilboa. The makings of a tumor rejection antigen. , 1999, Immunity.
[14] H. Rammensee,et al. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.
[15] L. Kanz,et al. Generation of Functional Human Dendritic Cells From Adherent Peripheral Blood Monocytes by CD40 Ligation in the Absence of Granulocyte-Macrophage Colony-Stimulating Factor , 1998 .
[16] H. Rackwitz,et al. Adipophilin is a specific marker of lipid accumulation in diverse cell types and diseases , 1998, Cell and Tissue Research.
[17] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[18] H. Rammensee,et al. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.
[19] L. Kanz,et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. , 1998, Blood.
[20] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.